Research programme: neurokinin-1 receptor antagonists - OPKO HealthAlternative Names: NK-1 antagonists - Schering-Plough
Latest Information Update: 16 Jul 2016
At a glance
- Originator Schering-Plough
- Developer OPKO Health
- Mechanism of Action Neurokinin 1 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Chemotherapy-induced nausea and vomiting